TMX Newsfile·2026-02-25 22:15Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Corcept Therapeutics Incorporated common stock during the specified Class Period, indicating potential legal recourse for affected investors [1]. Group 1: Class Action Details - The class action lawsuit is for purchasers of Corcept common stock between October 31, 2024, and December 30, 2025, inclusive [1]. - Investors who purchased shares during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - Interested parties can join the class action by visiting the provided link or contacting the law firm directly [3][6]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. - The firm has a history of significant settlements, including the largest securities class action settlement against a Chinese company and has recovered hundreds of millions for investors [4]. Group 3: Case Background - The lawsuit alleges that Corcept misrepresented the status of its New Drug Application (NDA) for relacorilant, claiming strong support from clinical trials while the FDA had raised concerns about the evidence [5]. - Defendants reportedly assured investors that there were no impediments to NDA approval, despite known risks that it might not be approved [5].